Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442720 plus adagrasib for KRAS G12C-mutant advanced non-small cell lung cancer
NL-OMON51317Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- May 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vociprotafib and adagrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoints: Incidence, nature and severity of TEAEs and SAEs and Objective response rate. Planned start May 2022; status: withdrawn.
02
Drugs
vociprotafibadagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON51317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51317.